Allergic inflammation.
A greater understanding of the basic mechanisms of allergic inflammation is pertinent to the development of new treatments. Previous studies have focused on the role of mediators of hypersensitivity and effector cells, including mast cells and eosinophils. Recent evidence suggests that IgE-dependent activation and tissue eosinophilia are under the local regulation of distinct cytokines. Originally described as products from T lymphocytes, these peptide messengers are produced by alternative cells, including mast cells, eosinophils and the respiratory epithelium. In vitro studies in murine models and using cloned human T lymphocytes indicate the preferential production of "Th2-type" cytokines, including interleukin-4 (IL-4) and IL-5. This review considers the evidence from in vivo studies in humans that "Th2-type" cytokines have a primary role in orchestrating both IgE-dependent events and local tissue eosinophilia. Novel therapeutic approaches might include a broad strategy directed against T lymphocytes, including the use of immunosuppressive agents or anti CD4 antibodies or more precise targeting of IL-4 and/or IL-5.
Durham
S R
SR
Department of Allergy & Clinical Immunology, National Heart & Lung Institute, London, England.
D000818:Animals; D001980:Bronchi / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D004804:Eosinophils / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology* / Q000628:therapy; D007249:Inflammation / Q000276:immunology; D009666:Nose / Q000276:immunology; D012867:Skin / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D016207:Cytokines